Deep brain stimulation in the treatment of dyskinesia and dystonia.

Abstract

Deep brain stimulation (DBS) has become a mainstay of treatment for patients with movement disorders. This modality is directed at modulating pathological activity within basal ganglia output structures by stimulating some of their nuclei, such as the subthalamic nucleus (STN) and the globus pallidus internus (GPi), without making permanent lesions. With the accumulation of experience, indications for the use of DBS have become clearer and the effectiveness and limitations of this form of therapy in different clinical conditions have been better appreciated. In this review the authors discuss the efficacy of DBS in the treatment of dystonia and levodopa-induced dyskinesias. The use of DBS of the STN and GPi is very effective for the treatment of movement disorders induced by levodopa. The relative benefits of using the GPi as opposed to the STN as a target are still being investigated. Bilateral GPi stimulation is gaining importance in the therapeutic armamentarium for the treatment of dystonia. The DYT1 forms of generalized dystonia and cervical dystonias respond to DBS better than secondary dystonia does. Discrimination between the diverse forms of dystonia and a better understanding of the pathophysiological features of this condition will serve as a platform for improved outcomes.

• Authors: Hiroki Toda, Clement Hamani, Andres Lozano
• Journal: Neurosurgical focus (Neurosurg Focus) Vol. 17 Issue 1 Pg. E2 (Jul 15 2004) ISSN: 1092-0684 [Electronic] United States
• PMID: 15264771 (Publication Type: Journal Article, Review)

Chemical References

• Molecular Chaperones
• TOR1A protein, human
• Levodopa

Topics

• Dyskinesia, Drug-Induced (etiology, therapy)
• Dyskinesias (classification, physiopathology, therapy)
• Dystonic Disorders (classification, physiopathology, surgery, therapy)
• Electric Stimulation Therapy (instrumentation, methods)
• Electrodes, Implanted
• Globus Pallidus (physiopathology)
• Humans
• Levodopa (adverse effects)
• Molecular Chaperones (genetics, physiology)
• Parkinson Disease (drug therapy, therapy)
• Stereotaxic Techniques
• Subthalamic Nucleus (physiopathology)
• Treatment Outcome